{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:49:50Z","timestamp":1764402590430},"reference-count":16,"publisher":"American Society for Microbiology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>This study compared the levels of immunogenicity and safety of diphtheria\u2013tetanus toxoid\u2013five-component acellular pertussis (DTaP<jats:sub>5<\/jats:sub>), inactivated poliovirus (IPV), and<jats:named-content content-type=\"genus-species\">Haemophilus influenzae<\/jats:named-content>type b (Hib) (DTaP<jats:sub>5<\/jats:sub>-IPV-Hib) and DTaP<jats:sub>3<\/jats:sub>-IPV\/Hib vaccines for study participants 3, 5, and 12 months of age. Post-dose 3 noninferiority criteria comparing DTaP<jats:sub>5<\/jats:sub>-IPV-Hib to DTaP<jats:sub>3<\/jats:sub>-IPV\/Hib using rates of seroprotection were demonstrated against diphtheria, tetanus, and polio types 1 to 3, but not for polyribosylribitol phosphate (PRP). While PRP did not meet noninferiority criteria, the seroprotection rate and geometric mean concentration (GMC) were high, indicating a clinically robust immune response. GMCs or titers for other antigens (including pertussis) and the safety profiles were generally similar between groups. Fully liquid DTaP<jats:sub>5<\/jats:sub>-IPV-Hib can be administered using the 3-, 5-, and 12-month vaccination schedule. (This study has been registered at ClinicalTrials.gov under registration no. NCT00287092.)<\/jats:p>","DOI":"10.1128\/cvi.00414-13","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T01:42:51Z","timestamp":1377135771000},"page":"1647-1653","source":"Crossref","is-referenced-by-count":10,"title":["Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of a Fully Liquid Combination Diphtheria\u2013Tetanus Toxoid\u2013Five-Component Acellular Pertussis (DTaP<sub>5<\/sub>), Inactivated Poliovirus (IPV), and Haemophilus influenzae Type b (Hib) Vaccine Compared with a DTaP<sub>3<\/sub>-IPV\/Hib Vaccine Administered at 3, 5, and 12 Months of Age"],"prefix":"10.1128","volume":"20","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven Arne","family":"Silfverdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Mwawasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"key":"key20180919073711_B1","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1016\/j.vaccine.2006.02.018","article-title":"A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole-cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age","volume":"24","author":"Kitchin","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073711_B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/adc.2005.076109","article-title":"Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age","volume":"92","author":"Kitchin","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"key20180919073711_B3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/adc.2004.052720","article-title":"DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation","volume":"90","author":"Slack","year":"2005","journal-title":"Arch. Dis. Child."},{"key":"key20180919073711_B4","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1016\/j.vaccine.2011.07.078","article-title":"Immunogenicity and safety of fully liquid DTaP(5)-IPV-Hib compared with DTaP(3)-IPV\/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study","volume":"29","author":"Grimprel","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073711_B5","volume-title":"Enhanced inactivated poliovaccine (IPV) in a fully liquid pentavalent DTaP-IPV-PRP-T combination: immunogenicity and safety in Mexican infants","author":"Castaneda","year":"2004"},{"key":"key20180919073711_B6","volume-title":"Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine with full primary IPV or sequential IPV-OPV in Mexican infants","author":"Castaneda","year":"2004"},{"key":"key20180919073711_B7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijid.2005.10.014","article-title":"A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis\u2013Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants","volume":"11","author":"Lin","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"key20180919073711_B8","article-title":"Immunogenicity and safety of a fully liquid DTaP-IPV-HiB vaccine in infants at 6, 10, and 14 weeks of age (EPI schedule)","volume-title":"Abstr. 3rd World Congr. Pediat. Infect. Dis.","author":"Capeding","year":"2002"},{"key":"key20180919073711_B9","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1016\/j.vaccine.2012.05.064","article-title":"Safety and immunogenicity of fully liquid DTaP5-IPV-Hib pediatric combination vaccine (Pediacel) compared to DTaP3-HBV-IPV\/Hib (Infanrix Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11\u201318 months of age: a phase III, modified double-blind, randomized, controlled, multicenter study","volume":"30","author":"Berner","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073711_B10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1155\/2007\/289842","article-title":"Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age","volume":"18","author":"Gold","year":"2007","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"key20180919073711_B11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijid.2007.01.006","article-title":"One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine","volume":"11","author":"Lin","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"key20180919073711_B12","unstructured":"US National Institutes of Health. 2012. April 13, posting date. Comparison of safety and immunogenicity of Pediacel\u2122 and Infanrix\u2122 IPV+Hib (Penta) given in a 3 dose schedule in infants. http:\/\/clinicaltrial.gov\/ct2\/show\/NCT00287092?term=A5I15&rank=1."},{"key":"key20180919073711_B13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat. Med."},{"key":"key20180919073711_B14","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-4475-7","volume-title":"Modelling binary data","author":"Collett","year":"1991"},{"key":"key20180919073711_B15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1185\/03007990152673837","article-title":"Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses","volume":"17","author":"Vidor","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"key":"key20180919073711_B16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1128\/JCM.26.1.72-78.1988","article-title":"Variable quantitation of Haemophilus influenzae type b anticapsular antibody by radioantigen binding assay","volume":"26","author":"Ward","year":"1988","journal-title":"J. Clin. Microbiol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00414-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:04Z","timestamp":1627591684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00414-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,26]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1128\/CVI.00414-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00414-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]}}}